US2005287197A1PendingUtilityA1

Method of treating insulin resistance, adult onset diabetes and metabolic syndrome x

40
Individually held — no corporate assignee on recordPriority: Oct 25, 2002Filed: Oct 23, 2003Published: Dec 29, 2005
Est. expiryOct 25, 2022(expired)· nominal 20-yr term from priority
Inventors:Seymour J. Kurtz
A61P 3/10A61P 3/00A61K 9/0019A61K 9/127
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of treating insulin resistance, adult onset diabetes, and metabolic syndrome X and its related complications, in mammalian subject is accomplished by intravenously administering to a mammalian subject, a therapeutically effective amount of a liposomal suspension of lipoprotein small unilamellar vesicles (SUVs) comprising predominantly phospholipids. The liposomal suspension is administered over a period of time, whereby in the levels of some or all of blood glucose, insulin, total cholesterol, LDL cholesterol, triglyceride, creatine kinase (CK), creatine kinase-MB (CK-MB), Hb-A1 c , lipoprotein (a), SGOT and SGPT fall back within the normal range or are significantly reduced.

Claims

exact text as granted — not AI-modified
1 . A method of treating insulin resistance, adult onset diabetes and metabolic syndrome X and its related complications in a mammalian subject, comprising intravenously administering to said mammalian subject a therapeutically effective amount of liposomal suspension of lipoprotein small unilamellar vesicles (SUV's), comprising predominantly phospholipids.  
   
   
       2 . The method of  claim 1 , wherein said phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylglycerol and phosphatidylserine.  
   
   
       3 . The method of  claim 2 , wherein said phosphatidylcholine is egg phosphatidylcholine.  
   
   
       4 . The method of  claim 2 , wherein said phosphatidylcholine is 1-palmitoyl, 2-oleoyl phosphatidylcholine, 1-palmitoyl, 2-linoleoyl phosphatidylcholine or a mixture thereon.  
   
   
       5 . The method of  claim 2 , wherein said phosphatidylcholine has a transition temperature of less than about 37° C.  
   
   
       6 . The method of  claim 5 , wherein said transition temperature is in the range of about −10 to 24° C.  
   
   
       7 . The method of  claim 1 , wherein said lipoprotein SUVs further comprise sphingomyelin, cholesterol or other sterols, in an amount less than about 40 mole percent.  
   
   
       8 . The method of  claim 1 , wherein said lipoprotein SUVs are empty.  
   
   
       9 . The method of  claim 1 , wherein said liposomal suspension is administered one to three times per week to said mammalian subject at a dose for each administration of about 50 mg-1 g total lipid/kg body weight.  
   
   
       10 . The method of  claim 9 , wherein said dose is about 200-450 mg total lipid/kg body eight.  
   
   
       11 . The method of  claim 1 , wherein said liposomal suspension is administered by intravenous injection or intravenous infusion.  
   
   
       12 . A liposomal suspension of lipoprotein small unilamellar vesicles (SUVs), comprising predominantly phospholipids for use in the preparation of a medicament for treating insulin resistance, adult onset diabetes and metabolic syndrom X and its related complications in a mammalian subject.  
   
   
       13 . The use of  claim 12 , wherein said phospholipids are selected from the group consisting of phosphatidylcholine, phosphatidylglycerol and phosphatidylserine.  
   
   
       14 . The use of  claim 13 , wherein said phosphatidylcholine is egg phosphatidylcholine.  
   
   
       15 . The use of  claim 13 , wherein said phosphatidylcholine is 1-palmitoyl, 2-oleoyl phosphatidylcholine, 1-palmitoyl, 2-linoleoyl phosphatidylcholine or a mixture thereof.  
   
   
       16 . The use of  claim 13 , wherein said phosphatidylcholine has a transition temperature of less than about 37° C.  
   
   
       17 . The use of  claim 16 , wherein said transition temperature is in the range of about −10 to 24° C.  
   
   
       18 . The use of  claim 12 , wherein said lipoprotein SUVs further comprise sphingomyelin, cholesterol or other sterols, in an amount less than about 40 mole percent.  
   
   
       19 . The use of  claim 12 , wherein said lipoprotein SUVs are empty.  
   
   
       20 . The use of  claim 12 , wherein said medicament is suitable for administration one to three tim4es per week to said mammalian subject at a does for each administration of about 50 mg-1 g total lipid/kg body weight.  
   
   
       21 . The use of  claim 20 , wherein said does is about 200-450 mg total lipid/kg body weight.  
   
   
       22 . the use of  claim 12 , wherein said medicament is suitable for administration by intravenous injection or intravenous infusion.

Join the waitlist — get patent alerts

Track US2005287197A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.